Article
Does anti-p53 antibody status predict for clinical outcomes in metastatic colorectal cancer patients treated with fluoropyrimidine, oxaliplatin, plus bevacizumab as first-line chemotherapy?
BMC cancer - 21 Oct 2015
Osumi Hiroki, Shinozaki Eiji, Suenaga Mitsukuni, Kumekawa Yosuke, Ogura Mariko, Ozaka Masato, Matsusaka Satoshi, Chin Keisho, Yamamoto Noriko, Mizunuma Nobuyuki
Abstract excerpt
BACKGROUND: TP53 gene mutation is widely known as one of the determinants of impaired chemosensitivity. p53 is a tumor-suppressor protein in humans encoded by the TP53 gene. Some studies have shown that TP53 gene mutation and accumulation of the p53 protein are closely related with serum anti-p53 antibody positivity. This study aimed to evaluate the predictive significance of the serum p53 antibody status in...
Read the complete abstract on PubMedTopics
Share this publication in a Topic to start or enrich a Post.